During a live event, Rushang Patel, MD, PhD, and participants discussed referral timing, bridging, and payer barriers that shape access to cellular therapy in early relapsed multiple myeloma.
Advertisement
Advertisement
Trending on Targeted Onc
1
Dr Chauhan on DLL3 Expression and Obrixtamig Outcomes in DAREON-7
2
FDA Approves OncoMate MSI Dx For Pembrolizumab in MSI-H Tumors
3
Phase 3 Results Point to a Path Forward for Cancer Vaccines
4
FDA Approves Durvalumab-EV Combo, Expanding MIBC Treatment Options
5